NCT02302469 - Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2017

Study Completion Date

April 30, 2017

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Revlimid

Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).

Trial Locations (7)

59037

Chru Lille, Lille

62307

CH LENS, Lens

63000

Ch Clermond Ferrand, Clermond Ferrand

64109

Centre Hospitalier de la côte basque, Bayonne

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75651

Groupe hospitalier Pitié Salpétrière, Paris

44 093

Ch Nantes, Nantes